MNMD Research | Milton Maxwell

Upcoming Earnings

Report date

≈ Oct 31, 2025 (tomorrow)

Key Stats

Market Cap

982.30M

P/E (TTM)

-

Basic EPS (TTM)

-1.34

Dividend Yield

0%

Recent Filings

8-K

10/29/25Oct 29, 2025

8-K

9/4/25Sep 4, 2025

8-K

7/31/25Jul 31, 2025

10-Q

7/31/25Jul 31, 2025

8-K

6/16/25Jun 16, 2025

About

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.

CEO

Mr. Robert Barrow

IPO

11/15/2016

Website

https://www.mindmed.co

Employees

74

Sector

Healthcare

Industry

Biotechnology